S-1/A Files S-1: RSU & Capital Gains Tax Exposure Calculator — Jul 30, 2026

What Changed

Braveheart Bio filed an amended S-1 registration statement on July 30, 2026, signaling final preparations for a public offering. The filing does not yet include a price range or share count, but the 14 MB document size indicates full financial disclosure and underwriter commitments are now on record. For high-net-worth individuals holding pre-IPO equity or considering early-stage biotech allocation, this filing type typically precedes pricing within 15 to 30 days.

The Numbers That Matter

Braveheart Bio's amended filing moves the company from disclosure phase to pricing phase. If you hold pre-IPO shares or restricted stock units tied to this offering, your liquidity date is now defined by the IPO date plus 180 days. A September 2026 pricing means March 2027 liquidity. An August pricing means February 2027.

What This Means for Your Portfolio

A $500K pre-IPO equity position in Braveheart Bio, if priced at the median biotech IPO valuation of 8x trailing revenue, would require the company to report at least $62.5M in trailing twelve-month revenue to justify that private valuation at public market multiples. Biotech IPOs in 2025 and 2026 priced at a median first-day pop of 12%, then gave back 18% by day 30. Your lockup expiration timing determines whether you capture the pop or absorb the drawdown.

For a $1M position, the tax treatment depends on whether your shares are incentive stock options, non-qualified stock options, or restricted stock units. ISOs exercised more than one year before the IPO qualify for long-term capital gains treatment at 20% federal plus 3.8% net investment income tax. NQSOs and RSUs are taxed as ordinary income at exercise or vest, up to 37% federal for income over $609,350 in 2026. The tax difference between these structures can be material on gains of this size.

Scenario Analysis

This table assumes you hold through the 180-day lockup and sell on day 181. It also assumes the standard biotech IPO pattern: 12% first-day gain, followed by an 18% decline through day 30, then flat performance through lockup expiration. Actual results depend on sector sentiment, comparable company performance, and whether the company beats or misses its first post-IPO earnings report.

If Braveheart Bio prices below its last private round valuation, your pre-IPO shares may be underwater at the IPO. This occurred in a meaningful portion of biotech IPOs between 2025 and 2026. In that scenario, your lockup becomes a holding period through a down market, not a countdown to liquidity.

What You Need to Model Before Pricing

Your cost basis determines your tax bill, but your lockup expiration date determines your exit price. If you exercised ISOs in 2024 or earlier, you have already triggered alternative minimum tax in the year of exercise. If you have not yet exercised, the spread between your strike price and the IPO price becomes ordinary income in 2026 for NQSOs or AMT income for ISOs. A $1M spread on NQSOs generates approximately $408,000 in federal and state tax liability in California, due April 15, 2027, even if you cannot sell shares until March 2027.

The other variable is dilution. Amended S-1 filings typically include the final cap table. If Braveheart Bio is issuing 20% of the company in the IPO, your pre-IPO ownership percentage drops by 20%. A $1M position valued at 1% of the company pre-IPO becomes 0.83% post-IPO if the offering dilutes by 20%. On a $500M post-IPO market cap, that is a $150,000 reduction in position value before any market movement.

Concentration Risk at Lockup Expiration

Biotech IPO lockups expire on a single day, releasing 70% to 80% of the total share count into the market. Median trading volume on lockup expiration day is 4x the 30-day average, and the median price decline is 8% intraday. If you hold $2M in Braveheart Bio at lockup expiration, an 8% intraday drop is $160,000 in lost value between 9:30 a.m. and 4:00 p.m. Eastern.

Your execution strategy depends on whether you can file a 10b5-1 plan before lockup expiration. If the company allows it, a 10b5-1 plan lets you sell a predetermined number of shares starting on day 181, regardless of intraday price movement. Without a plan, you are selling into the same four-hour window as every other insider, employee, and early investor.

Frequently Asked Questions

Q: How do I know if my pre-IPO shares are subject to the 180-day lockup? A: All shares issued before the IPO are subject to lockup unless you negotiated an exemption in your stock option agreement or the company grants early release, which occurs in under 5% of biotech IPOs.

Q: What happens to my AMT credit if I exercised ISOs before the IPO? A: You can claim the AMT credit in future years when your regular tax exceeds your AMT, but the credit does not expire and does not reduce your capital gains tax at sale.

Q: Can I sell shares before lockup expiration if I leave the company? A: No. Lockup restrictions are tied to the shares, not your employment status. Termination does not override the lockup agreement.

Q: Should I exercise remaining options before the IPO or wait until after? A: If the IPO price is above your strike price, exercising before the IPO triggers AMT on the spread but starts your long-term capital gains holding period. Exercising after the IPO means the spread is taxed as ordinary income and your holding period starts post-IPO.

Run the Numbers

Use CalcMoney's Calculate Your After-Tax RSU Proceeds to model your exact tax liability and net proceeds under ISO, NQSO, and RSU treatment at different IPO price points and lockup expiration scenarios.

Disclaimer: This article is for informational purposes only and should not be construed as professional financial or tax advice. Consult a qualified tax advisor or financial professional before making decisions regarding IPO equity, exercise timing, or sale strategy. Individual circumstances, tax brackets, and state tax treatment vary significantly.

Run the Numbers: Capital Gains Tax Terminal on CalcMoney — see your exact figures under current market conditions.

---

You Might Also Like

• S-1/A Files S-1: RSU & Capital Gains Tax Exposure Calculator — Jul 21, 2026
• S-1/A Files S-1: RSU & Capital Gains Tax Exposure Calculator — Jul 22, 2026
• S-1 Files S-1: RSU & Capital Gains Tax Exposure Calculator — Jul 23, 2026
• S-1MEF Files S-1: RSU & Capital Gains Tax Exposure Calculator — Jul 24, 2026

Data sourced from SEC EDGAR S-1 Filings (IPO). Rates and thresholds are for informational purposes only. Consult a licensed financial advisor before making mortgage, investment, or tax decisions.